Revenues for pharmaceuticals industry in Saudi Arabia are estimated to rise at a 5.20% CAGR through 2034. The overall demand for pharmaceuticals in Saudi Arabia is likely to surge, crossing a valuation of US$ 10,113.1 million in 2024. By 2034, sales projections for pharmaceuticals in Saudi Arabia indicate attaining a valuation of US$ 16,789.6 million.
Key Trends Boosting Sales through 2034:
| Attributes | Details |
|---|---|
| Industry Size in Saudi Arabia in 2024 | US$ 10,113.1 million |
| Expected Industry Size of Saudi Arabia in 2034 | US$ 16.789.6 million |
| Forecasted CAGR between 2024 and 2034 | 5.20% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Attributes | Details |
|---|---|
| Historical CAGR (2019 to 2023) | 9.0% |
| Forecasted CAGR (2024 to 2034) | 5.20% |
The Saudi Arabian pharmaceutical industry expanded at a 9.0% CAGR from 2019 to 2023. The Saudi government has aggressively promoted economic diversification and the growth of the healthcare industry. Initiatives like Vision 2030, unveiled in 2016, attempt to minimize the Kingdom’s reliance on oil while also focusing on developing a more varied and sustainable economy. The expansion of the pharmaceutical sector in Saudi Arabia is facilitated by investments in research and development as well as infrastructure related to healthcare.
Saudi Arabia's population is expanding quickly, and the country is seeing a rise in the frequency of chronic illnesses and pharmaceutical products. Due to the expanding healthcare demands, pharmaceutical firms now have more opportunities to grow and satisfy the demand for drugs.
By enacting reforms, Saudi Arabia has liberalized its economy and opened it up to international investment, particularly in the pharmaceutical industry. As a result, more foreign pharmaceutical businesses are now present in the Saudi pharmaceutical sector, contributing knowledge, funds, and technology.
Access to healthcare services has increased throughout Saudi Arabia due to investments in the country's healthcare infrastructure, which includes clinics, hospitals, and pharmacies. As a result, there is now a greater need than ever for pharmaceuticals to satisfy the demands of an expanding patient base.
The demand for pharmaceuticals in Saudi Arabia is predicted to rise at 5.20% through 2034. Although the growth rate is lower than the historical period, ongoing investments in healthcare infrastructure are likely to bolster pharmaceutical demand in Saudi Arabia.
Saudi Arabia can anticipate an increase in medical tourism as the nation works to establish itself as a regional center for healthcare. As a result, pharmaceutical enterprises are going to have more chances to offer medical services and goods to a global patient population.
Principal Consultant
| Leading Drug Type for Pharmaceuticals in Saudi Arabia | Branded Drugs |
|---|---|
| Total Value Share (2024) | 72% |
Eighty percent of Saudi Arabia's pharmaceuticals are imported from foreign nations. Merely thirty percent of Saudi Arabia's medicines and a small fraction of branded medication output are domestically manufactured. Branded drugs from various leading giants are highly preferred in Saudi Arabia due to their perceived quality and efficacy over generic drugs.
Even when generic medications have the same active components as their branded equivalents, consumers tend to see branded medications as more inventive and potent. In economies where consumers place a premium on perceived efficacy, the notion that branded medications provide better outcomes can increase demand.
Certain pharmaceutical firms provide patients discounts or financial help through their loyalty programs or assistance programs for branded medications. These initiatives affect patient decisions and raise the demand for branded pharmaceuticals.
| Leading Drug Class for Pharmaceuticals in Saudi Arabia | Small Molecules |
|---|---|
| Total Value Share (2024) | 86% |
It is normal practice to treat common health issues, including infections, diabetes, and cardiovascular illnesses, with small molecules. Since these illnesses are becoming more common in Saudi Arabia, there is likely to be an enormous demand for small-molecule medications that target these medical disorders.
Small molecule medications are often accessible and available, particularly in generic form. When it comes to healthcare systems that strive for universal coverage and availability of pharmaceutical treatments, this accessibility guarantees a consistent supply of necessary pharmaceuticals, which adds to their appeal.
Complex biologics are typically more expensive to develop than small molecules, especially generic variants. Small molecules' affordability fuels demand in healthcare systems where cost is an integral factor, particularly when treating common health issues.
Regulatory bodies around the globe, including Saudi Arabia, typically have well-defined procedures implemented for examining and approving small molecule medications. Small molecules are in high demand in this sector because their regulatory routes are well-known, which helps speed up and simplify the clearance procedure.
The pharmaceutical industry in Saudi Arabia is marked by a competitive and dynamic environment that both domestic and foreign firms fuel. Various businesses compete for dominance in this industry, hoping to take advantage of the nation's changing healthcare requirements.
Companies like Tabuk Pharmaceuticals, Jamjoom Pharma, and Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) are important participants in the domestic market and significantly affect the sector's expansion. These businesses use their knowledge of the local market, well-established distribution networks, and compliance with laws and regulations to stay one step ahead of the competition.
Strategies for Key Players to Tap into Potential Growth Opportunities
Recent Developments
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attribute | Details |
|---|---|
| Estimated Industry Size in 2024 | US$ 10,113.1 million |
| Projected Industry Size in 2034 | US$ 16,789.6 million |
| Anticipated CAGR between 2024 to 2034 | 5.20% CAGR |
| Historical Analysis of Demand for Pharmaceuticals in Saudi Arabia | 2019 to 2023 |
| Demand Forecast for Pharmaceuticals in Saudi Arabia | 2024 to 2034 |
| Report Coverage | Industry Size, Industry Trends, Analysis of key factors influencing Pharmaceuticals Adoption in Saudi Arabia, Insights on Global Players and their Industry Strategy in Saudi Arabia, Ecosystem Analysis of Local and Regional Saudi Arabia Manufacturers |
| Key Companies Profiled | Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO); Tabuk Pharmaceuticals; Hikma Pharmaceuticals; Julphar Saudi Arabia; Jamjoom Pharma; Modern Pharmaceutical Company (MPC); Ameco Pharmaceutical Company; Tadawi; Al Nahdi Medical Company; Sipco (Saudi Industrial Products Company) |
The expected CAGR until 2034 stands at 5.20%.
Anticipated demand for pharmaceuticals in Saudi Arabia is projected to reach US$ 16,789.6 million by 2034.
The rising prevalence of chronic diseases highly influences demand in Saudi Arabia.
Pharmaceutical manufacturers emphasize continuous innovation in product offerings.
Branded drugs are highly popular in Saudi Arabia.
1. Executive Summary 1.1. Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Manufacturer and Consumption Statistics 3.12. Import and Export Statistics 4. Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product Type, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product Type, 2024 to 2034 5.3.1. Prescription Products 5.3.1.1. Branded Drugs 5.3.1.2. Generic Drugs 5.3.2. Over The Counter (OTC) Products 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Product Type, 2024 to 2034 6. Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Disease Type, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Disease Type, 2024 to 2034 6.3.1. Cardiovascular Diseases 6.3.2. Diabetes 6.3.3. Cancer 6.3.4. Obesity 6.3.5. Infectious Diseases 6.3.6. Others 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Disease Type, 2024 to 2034 7. Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2024 to 2034 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 8. Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2024 to 2034 8.3.1. Riyadh Province 8.3.2. Mecca Province 8.3.3. Eastern Province 8.3.4. Medina Province 8.3.5. Jazan Province 8.3.6. Asir Province 8.3.7. Rest of Saudi Arabia 8.4. Market Attractiveness Analysis By Region 9. Riyadh Province Market Analysis 2019 to 2023 and Forecast 2024 to 2034 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Product Type 9.2.2. By Disease Type 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Product Type 9.3.2. By Disease Type 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Mecca Province Market Analysis 2019 to 2023 and Forecast 2024 to 2034 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Product Type 10.2.2. By Disease Type 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Product Type 10.3.2. By Disease Type 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Province Market Analysis 2019 to 2023 and Forecast 2024 to 2034 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Product Type 11.2.2. By Disease Type 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Product Type 11.3.2. By Disease Type 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. Medina Province Market Analysis 2019 to 2023 and Forecast 2024 to 2034 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Product Type 12.2.2. By Disease Type 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Product Type 12.3.2. By Disease Type 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. Jazan Province Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Product Type 13.2.2. By Disease Type 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Product Type 13.3.2. By Disease Type 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Asir Province Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Product Type 14.2.2. By Disease Type 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Product Type 14.3.2. By Disease Type 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Rest of Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Region 15.2.2. By Product Type 15.2.3. By Disease Type 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Region 15.3.2. By Product Type 15.3.3. By Disease Type 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product Type 16.3.3. By Disease Type 16.3.4. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. SPIMACO 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Tabuk s Manufacturing Co. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Julphar 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Jamjoom Pharma 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. GlaxoSmithKline plc 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Pfizer Inc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Novartis AG 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Sanofi 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. AstraZeneca Plc 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Astellas Pharma 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Pharmaceutical Industry Analysis in Saudi Arabia
